Bridge Therapy Between Induction, ASCT May Slow Neuroblastoma
Three - year event - free survival significantly improved for patients with end - induction stable metastatic disease receiving bridge therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 6, 2022 Category: Cancer & Oncology Tags: Neurology, Oncology, Pathology, Pediatrics, Journal, Source Type: news

Bridge Therapy Between Induction, ASCT May Slow Neuroblastoma
MONDAY, June 6, 2022 -- For patients with high-risk neuroblastoma with end-induction stable metastatic disease, postinduction bridge therapy before autologous stem cell transplantation (ASCT) is associated with better outcomes, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2022 Category: Pharmaceuticals Source Type: news

Cancer Outcome Disparities Not Fully Explained by Race, Socioeconomic Factors
(MedPage Today) -- Enrollment in clinical trials failed to overcome factors leading to worse survival for Hispanic children with high-risk neuroblastoma, a large retrospective analysis showed. The Hispanic subgroup had a 5-year overall survival... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 27, 2022 Category: Hematology Source Type: news

Clarity launching trial for prostate cancer therapy
Clarity Pharmaceuticals is launching an investigator-initiated trial that wil...Read more on AuntMinnie.comRelated Reading: Clarity hits milestone in study of radiopharmaceutical NorthStar partners with Clarity, Monopar FDA grants rare disease designation to Clarity agent Clarity's breast imaging agent enters clinical trial Clarity begins trial for pediatric neuroblastoma therapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 24, 2022 Category: Radiology Source Type: news

The cancer vaccine that saved our boy should be free on the NHS
WHEN Claire and Mike Scott's three-year-old son was diagnosed with neuroblastoma their world fell apart. Hearts breaking, they had to watch as little Liam went through a whole year of gruelling procedures - chemotherapy, surgery, radiotherapy, immunotherapy and bone marrow treatment. (Source: Daily Express - Health)
Source: Daily Express - Health - February 8, 2022 Category: Consumer Health News Source Type: news

Parents of girl, 4, who is battling rare neuroblastoma cancer are raising £250,000
Florentina Burton, from Braintree, Essex, was diagnosed with neuroblastoma in May last year, after doctors found a tumour on her kidney. (Source: the Mail online | Health)
Source: the Mail online | Health - January 16, 2022 Category: Consumer Health News Source Type: news

Clarity hits milestone in study of radiopharmaceutical
Radiopharmaceutical developer Clarity Pharmaceuticals has completed patien...Read more on AuntMinnie.comRelated Reading: NorthStar partners with Clarity, Monopar Clarity's breast imaging agent enters clinical trial Clarity begins trial for pediatric neuroblastoma therapy Clarity, ImaginAb team to develop theranostic agents NorthStar inks supply deal with Clarity (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 11, 2021 Category: Radiology Source Type: news

Safety concerns raised for neuroblastoma candidate drug
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Then researchers identified safety concerns with the experimental drug that have implications for current clinical trials in adults. The study appears today in Nature Communications. (Source: World Pharma News)
Source: World Pharma News - November 9, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Therapy using dual immune system cells effectively controls neuroblastoma
A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was highly effective in mice implanted with human neuroblastoma tissue, report researchers from the UNC Lineberger Comprehensive Cancer Center and the UNC School of Medicine. (Source: World Pharma News)
Source: World Pharma News - September 23, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Consumer Health: Childhood cancer
September is Childhood Cancer Awareness Month, which makes this a good time to learn about three of the most common types of cancers in children: acute lymphocytic leukemia, neuroblastoma and pediatric brain tumors. Acute lymphocytic leukemia Acute lymphocytic leukemia is a cancer of the blood and bone marrow. It's the most common type of cancer in children, and treatments result in a good chance for a cure. Acute lymphocytic leukemia also can occur in adults, though… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 6, 2021 Category: Databases & Libraries Source Type: news

Oncotarget: Modulating Tau Post-translational modifications and cytoskeletal network
(Impact Journals LLC) EGCG, a green tea polyphenol, as a modulator of in vitro methylglyoxal-induced Tau glycation and its impact on reducing advanced glycation end products in neuroblastoma cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news

Metabolic enzyme promotes neuroblastoma aggressiveness
(Boston University School of Medicine) High-risk neuroblastoma is an aggressive childhood cancer with poor treatment outcomes. Despite intensive chemotherapy and radiotherapy, less than 50 percent of these children survive for five years. While the genetics of human neuroblastoma have been extensively studied, actionable therapeutics are limited. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

Researchers on a mission to fight deadly childhood cancer
(University of South Australia) Neuroblastoma is the deadliest and most common solid cancer in young children the world over, accounting for 15 per cent of all childhood cancer deaths. But Australian researchers are taking the first steps to find the cause and better treatments for this devastating disease which affects children under the age of five. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 3, 2021 Category: Cancer & Oncology Source Type: news

Nerve tumor in children: better tolerable chemotherapy without loss of efficacy
(St. Anna Children's Cancer Research Institute) The initial chemotherapy of aggressive childhood nerve tumors, so-called high-risk neuroblastomas, is crucial for ultimate survival. It has now been shown that the chemotherapy regimen used by the European Neuroblastoma Study Group is equally efficacious but better tolerated than a highly effective regimen from the US. This was the conclusion of an international trial coordinated by St. Anna Children's Cancer Research Institute. The study was published in the prestigious Journal of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 21, 2021 Category: International Medicine & Public Health Source Type: news

' Remarkable' Results for Targeted Therapy of Rare CNS Tumors'Remarkable' Results for Targeted Therapy of Rare CNS Tumors
The results come from three small studies of targeted therapy for papillary craniopharyngiomas (PCPs), gliomas and neuroblastomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news